Now is "an exciting time" to be investing in the biotech sector, because of the wave of innovation in the pipeline and the historically low P/E ratios available, according to Geoff Hsu of OrbiMed Advisors, the manager of the £70m London-listed Biotech Growth Trust PLC (BIOG)'.
Not only are biotech stocks trading at forward P/Es of just 18x, but their Price/Earnings to Growth (PEG) ratios are below those of the larger pharmaceutical companies, something "we've never really seen...
Irish border, resignations, market volatility and more
Revealed – successes across all 11 categories
Fidelity International multi-asset CIO James Bateman talks to Julian Marr about recent market volatility, portfolio positioning and his thoughts on the coming year
Follows Phil Young
‘Positive so far’